» Authors » Chengfu Xu

Chengfu Xu

Explore the profile of Chengfu Xu including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 134
Citations 2381
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Shen Q, Xu C
Aliment Pharmacol Ther . 2025 Feb; 61(7):1268-1269. PMID: 40019255
No abstract available.
2.
Guo Y, Huang H, Yang L, Shen Q, Liu Z, Wang Q, et al.
J Biol Chem . 2025 Feb; 301(3):108285. PMID: 39938799
Metabolic dysfunction-associated steatohepatitis (MASH) is a complicated process that contributes to end-stage liver disease and, eventually, hepatocellular carcinoma. Hepatocyte apoptosis, a well-defined form of cell death in MASH, is considered...
3.
Cai C, Luo H, Peng J, Zhen X, Shen X, Xi X, et al.
Mol Ther . 2025 Feb; PMID: 39905730
Metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of metabolic dysfunction-associated fatty liver disease (MAFLD), is a leading cause of liver disease worldwide and can progress to cirrhosis and cancer. Despite...
4.
Shen Q, Xu C
Aliment Pharmacol Ther . 2024 Oct; 60(11-12):1662-1663. PMID: 39466008
No abstract available.
5.
Chen S, Xu L, Yan L, Zhang J, Zhou X, Wang J, et al.
Endoscopy . 2024 Oct; PMID: 39447610
Background:  Autoimmune gastritis (AIG), distinct from Helicobacter pylori-associated atrophic gastritis (HpAG), is underdiagnosed due to limited awareness. This multicenter study aimed to develop a novel endoscopic artificial intelligence (AI) system...
6.
Liu P, Song X, Chen Q, Cen L, Tang C, Yu C, et al.
J Biol Chem . 2024 Oct; 300(11):107876. PMID: 39395794
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. Ubiquitin-specific peptidase 25 (USP25) in adipocytes has been proven to be involved in insulin resistance, a noteworthy...
7.
Tao L, Yang X, Ge C, Zhang P, He W, Xu X, et al.
Cell Metab . 2024 Aug; 36(10):2190-2206.e5. PMID: 39142286
The complex etiological factors associated with metabolic dysfunction-associated fatty liver disease (MAFLD), including perturbed iron homeostasis, and the unclear nature by which they contribute to disease progression have resulted in...
8.
Xie J, Lin P, Hou L, Miao M, Zhu Z, Li Y, et al.
Diabetol Metab Syndr . 2024 Aug; 16(1):192. PMID: 39118126
Background: We aimed to investigate the post-cessation T2DM risk in male NAFLD and NAFLD-free smokers in a 7-year cohort study. Methods: The study population was male adults who underwent annual...
9.
Liu Z, Huang H, Xie J, Xu Y, Xu C
Nat Commun . 2024 May; 15(1):3707. PMID: 38697980
Nuclear magnetic resonance (NMR)-based plasma fatty acids are objective biomarkers of many diseases. Herein, we aim to explore the associations of NMR-based plasma fatty acids with the risk of hepatocellular...
10.
Xu M, Lin Y, Yang N, Li J, Li L, Ding H, et al.
Rev Assoc Med Bras (1992) . 2024 Mar; 70(3):e20230963. PMID: 38451586
Objective: The aim of this study was to explore the correlation between skeletal muscle content and the presence and severity of metabolic dysfunction-associated fatty liver disease in patients with metabolic...